Search results for "Grading"

showing 10 items of 282 documents

Effects of p63 expression on survival in oral squamous cell carcinoma

2007

BACKGROUND: P63 is the protein codified by p63 gene, a p53 gene homolog, known for its pivotal role in cell cycle regulation, and involved in the tumor differentiation. Aims of the present study were to assess the frequency and pattern of p63 protein expression in oral squamous cell carcinoma (OSCC) in relation to the main tumour characteristics and to verify whether p63 can be considered a marker of prognosis in patients with OSCC. MATERIAL AND METHODS: In a retrospective study, a cohort of 64 OSCC patients was investigated for p63 protein expression and its cellular localization by immunohistochemistry (monoclonal mouse anti-human p63 protein-clone 4A4). After grouping by p63 expression, …

OncologyAdultMaleCancer Researchmedicine.medical_specialtyPathologySurvival rateBiologyOSCCInternal medicinemedicineBiomarkers TumorCox regression analysisHumansGrading (tumors)GeneSurvival rateCellular localizationAgedNeoplasm StagingCox regression analysis; OSCC; p53 family; p63; Survival rate;p63integumentary systemTumor Suppressor ProteinsRetrospective cohort studyGeneral MedicineMiddle AgedPrognosisSurvival Analysisp63 p53 family OSCC Survival rate Cox regression analysisDNA-Binding Proteinsstomatognathic diseasesOncologyCohortMonoclonalCarcinoma Squamous CellTrans-ActivatorsImmunohistochemistryFemaleMouth NeoplasmsOSCCsense organsp53 familyp53 familyCox regressionTranscription Factors
researchProduct

Multivariable non-invasive association of isocitrate dehydrogenase mutational status in World Health Organization grade II and III gliomas with advan…

2020

Aim To investigate multivariable analyses for noninvasive association of the isocitrate dehydrogenase (IDH) mutational status in grade II and III gliomas including evaluation of T2 mapping-sequences. Methods Magnetic resonance imaging (MRI) examinations with histopathologically proven World Health Organization grade II and III gliomas were retrospectively enrolled. Multivariate receiver operating characteristics (ROC) analyses to associate IDH mutational status were performed containing quantitative T2 mapping analyses and qualitative characteristics (sex, age, localization, heterogeneity, oedema, necrosis and diameter). Relaxation times were calculated pixelwise by means of standardized RO…

OncologyAdultMalemedicine.medical_specialtyT2 mappingWorld Health OrganizationWorld health030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineMagnetic resonance imaging T2 mappingGliomaInternal medicinemedicineMutational statusHumansRadiology Nuclear Medicine and imagingNeoplastic DiseasesAgedRetrospective StudiesAged 80 and overbusiness.industryBrain NeoplasmsNon invasiveGeneral MedicineGliomaMiddle Agedmedicine.diseasePrognosisMagnetic Resonance ImagingIsocitrate DehydrogenaseMRI - Magnetic resonance imagingIsocitrate dehydrogenaseMutationFemaleNeurology (clinical)Neoplasm Gradingbusiness030217 neurology & neurosurgery
researchProduct

Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer

2015

Aim To evaluate the optimal time interval from definitive surgery to commencing chemotherapy in early breast cancer (EBC). Patients and methods The relationship between time to initiation of adjuvant chemotherapy (TTC), calculated in weeks, and disease-free (DFS) or overall survival (OS), was assessed in 921 EBC patients with rapidly proliferating tumours (thymidine labelling index >3% or G3 or Ki67 >20%), randomised in a phase III clinical trial (NCT01031030) to receive chemotherapy with or without anthracyclines (epirubicin → cyclophosphamide, methotrexate and fluorouracil (CMF) versus CMF → epirubicin versus CMF). DFS, OS and 95% confidence intervals (95% confidence interval (CI)) …

OncologyCancer ResearchTime Factorsmedicine.medical_treatmentKaplan-Meier EstimateRisk FactorsAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesProspective cohort studyMultivariate AnalysiAdjuvantMastectomyMedicine (all)Hazard ratioEarly breast cancerMiddle AgedTreatment OutcomeItalyOncologyChemotherapy AdjuvantFluorouracilDisease ProgressionFemaleBreast NeoplasmMastectomyHumanmedicine.drugRapidly proliferating tumourAdultmedicine.medical_specialtyTime FactorBreast NeoplasmsDisease-Free SurvivalTime-to-TreatmentAdjuvant chemotherapy; Early breast cancer; Rapidly proliferating tumour; Time to initiation of adjuvant chemotherapy; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy Adjuvant; Disease Progression; Disease-Free Survival; Female; Humans; Italy; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Proportional Hazards Models; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome; Cell Proliferation; Mastectomy; Time-to-Treatment; Cancer Research; Oncology; Medicine (all)Internal medicinemedicineChemotherapyHumansAgedNeoplasm StagingProportional Hazards ModelsCell ProliferationChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryProportional hazards modelRisk FactorAdjuvant chemotherapy; Early breast cancer; Rapidly proliferating tumour; Time to initiation of adjuvant chemotherapy; Cancer Research; OncologyConfidence intervalSurgeryAdjuvant chemotherapyProspective StudieTime to initiation of adjuvant chemotherapyMultivariate AnalysisProportional Hazards ModelMethotrexateNeoplasm Gradingbusiness
researchProduct

PO-182 The upregulation of EPDR1 is related to tumour invasiveness in a cohort of localised colorectal cancer patients

2018

Introduction Colorectal cancer (CRC) represents a relevant public health problem. Despite new therapeutic advances, prognosis of patients diagnosed with advanced disease is still poor. The identification of new markers involved in the mechanisms of invasiveness represents a priority in order to better understand cancer development and generate new therapeutic targets. We describe here the possible role of EPDR1, a gene not yet well characterised, which encodes a protein related to ependymins, a family of piscine transmembrane proteins involved in cell adhesion. To evaluate the role of EPDR1, a translational investigation was planned to explore the consequences of the upregulation of EPDR1 i…

OncologyCancer Researchmedicine.medical_specialtyGene knockdownNecrosisCell growthColorectal cancerbusiness.industrymedicine.diseaseOncologyDownregulation and upregulationInternal medicineCohortmedicineGene silencingmedicine.symptombusinessGrading (tumors)ESMO Open
researchProduct

Radiomic analysis reveals DCE-MRI features for prediction of molecular subtypes of breast cancer.

2017

The purpose of this study was to investigate the role of features derived from breast dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and to incorporated clinical information to predict the molecular subtypes of breast cancer. In particular, 60 breast cancers with the following four molecular subtypes were analyzed: luminal A, luminal B, human epidermal growth factor receptor-2 (HER2)-over-expressing and basal-like. The breast region was segmented and the suspicious tumor was depicted on sequentially scanned MR images from each case. In total, 90 features were obtained, including 88 imaging features related to morphology and texture as well as dynamic features from tumor and …

OncologyCancer Treatmentlcsh:MedicineInvasive Ductal CarcinomaLogistic regression030218 nuclear medicine & medical imagingDiagnostic Radiology0302 clinical medicineMathematical and Statistical TechniquesBreast TumorsImage Processing Computer-AssistedMedicine and Health Scienceslcsh:ScienceMultidisciplinarymedicine.diagnostic_testHuman epidermal growth factorRadiology and ImagingMiddle AgedMagnetic Resonance ImagingOncology030220 oncology & carcinogenesisArea Under CurvePhysical SciencesFemaleAlgorithmsStatistics (Mathematics)Research ArticleAdultmedicine.medical_specialtyImaging TechniquesImage processingBreast NeoplasmsResearch and Analysis MethodsCarcinomasSkewness03 medical and health sciencesBreast cancerText miningDiagnostic MedicineInternal medicineImage Interpretation Computer-AssistedBreast CancermedicineBiomarkers TumorHumansStatistical MethodsDifferentiated TumorsAgedNeoplasm StagingReceiver operating characteristicbusiness.industrylcsh:RCancers and NeoplasmsMagnetic resonance imagingLuminal amedicine.diseaseImage EnhancementProbability TheoryProbability Distributionlcsh:QNeoplasm GradingbusinessMathematicsForecastingPloS one
researchProduct

Combined histoarchitectural and cytological biopsy grading improves grading accuracy in low-grade prostate cancer

2011

Objectives:  Accurate tumor grading on prostate biopsy represents the mainstay for therapy planning. Biopsy undergrading is a persistent diagnostic dilemma with therapeutic relevance. We questioned whether Gleason grading combined with an established alternative grading system incorporating cytological parameters improves grading accuracy. Methods:  Needle biopsies of 968 patients and the corresponding radical prostatectomy specimens were graded according to the Gleason grading system. In addition, all biopsies were graded according to the histo- and cytological grading system of Helpap. Biopsy Gleason grade, as well as the combined Gleason/Helpap grade, was compared with the final Gleason …

OncologyGleason grading systemmedicine.medical_specialtyNeoplasm GradingProstate biopsymedicine.diagnostic_testProstatectomybusiness.industryUrologymedicine.medical_treatmenturologic and male genital diseasesmedicine.diseaseGleason Score 6Prostate cancerInternal medicineBiopsymedicineRadiologyGrading (education)businessneoplasmsInternational Journal of Urology
researchProduct

Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX ch…

2013

The GOLFIG-2 phase III trial was designed to compare the immunobiological activity and antitumor efficacy of GOLFIG chemoimmunotherapy regimen with standard FOLFOX-4 chemotherapy in frontline treatment of metastatic colorectal cancer (mCRC) patients. This trial was conceived on the basis of previous evidence of antitumor and immunomodulating activity of the GOLFIG regimen in mCRC. GOLFIG-2 is a multicentric open/ label phase III trial (EUDRACT: 2005-003458-81). Chemo-naive mCRC patients were randomized in a 1:1 ratio to receive biweekly standard FOLFOX-4 or GOLFIG [gemcitabine (1000 mg/m 2, day 1); oxaliplatin (85 mg/m2, day 2); levofolinate (100 mg/m2, days 1-2), 5-fluorouracil (5-FU) (400…

OncologyMaleCancer ResearchGranulocyte-macrophage-colonystimulating- factorOrganoplatinum Compoundsmedicine.medical_treatmentLeucovorinColorectal NeoplasmGastroenterologyDeoxycytidineFOLFOXAldesleukinPhase iii trialAntineoplastic Combined Chemotherapy ProtocolsImmunology and AllergyMedicineChemoimmunotherapyNeoplasm MetastasisAged 80 and overAldesleukinMiddle AgedNeoplasm MetastasiOxaliplatinColorectal carcinomaTreatment OutcomeFluorouracilFemaleFluorouracilColorectal NeoplasmsHumanmedicine.drugAdultmedicine.medical_specialtyImmunologyLymphocytes Tumor-InfiltratingChemoimmunotherapyInternal medicineHumansAgedPharmacologyChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryOrganoplatinum CompoundGranulocyte-Macrophage Colony-Stimulating FactorGemcitabineGemcitabineOxaliplatinRegimenInterleukin-2Neoplasm GradingbusinessJournal of immunotherapy (Hagerstown, Md. : 1997)
researchProduct

P-cadherin expression and survival rate in oral squamous cell carcinoma: an immunohistochemical study

2005

Abstract Background P-cadherin (P-cad) is a transmembrane molecule involved in the cell-cell adhesion and similar to E-cadherin (E-cad), but less investigated in oncology, especially in in vivo studies. Aims of the present study were to assess the prevalence of P-cad expression in oral squamous cell carcinoma (OSCC) and to verify whether P-cad can be considered a marker of prognosis in patients with OSCC. Methods In a retrospective study, a cohort of 67 OSCC patients was investigated for P-cad expression and its cellular localization by immunohistochemistry; some respective healthy margins of resection were similarly investigated as standard controls. After grouping for P-cad expression, OS…

OncologyMalePathologyCancer ResearchCytoplasmTime FactorsCohort StudiesSurgical oncologyCellular localizationMouth neoplasmAged 80 and overMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCadherinsPrognosisImmunohistochemistryTreatment OutcomeOncologycell-cell adhesionCarcinoma Squamous CellImmunohistochemistryRegression AnalysisFemaleMouth NeoplasmsResearch ArticleAdultmedicine.medical_specialtyAdolescentlcsh:RC254-282Internal medicinemedicineGeneticsBiomarkers TumorHumanscardiovascular diseasesGrading (tumors)Survival rateAgedProportional Hazards ModelsRetrospective StudiesModels StatisticalProportional hazards modelCadherinbusiness.industryCell MembraneCateninstomatognathic diseasesMultivariate AnalysisCadherinbusinessCell Adhesion Molecules
researchProduct

The Fuhrman grading system has no prognostic value in patients with nonsarcomatoid chromophobe renal cell carcinoma.

2014

The prognostic value of the Fuhrman nuclear grading system has been questioned for chromophobe renal cell carcinoma (chRCC) because this subtype frequently displays nuclear and nucleolar pleomorphism. The present study reevaluates this grading system in a series of patients with nonsarcomatoid chRCC. We identified 176 patients (3.6%) with nonsarcomatoid chRCC in a total of 4897 patients who underwent surgery for renal cell carcinoma at 5 centers in Germany between 1990 and 2010. The mean follow-up was 51.1 months. The 3 groups (G1 versus G2 versus G3/4) were comparable in terms of age, sex, tumor diameter, and lymph node metastasis. They only differed significantly in tumor stage (P = .01) …

OncologyMalemedicine.medical_specialtyChromophobe Renal Cell CarcinomaUrologyPathology and Forensic MedicineRenal cell carcinomaInternal medicineMedicineHumansSurvival rateCarcinoma Renal CellRetrospective StudiesNeoplasm Gradingbusiness.industryHistologyRetrospective cohort studyMiddle Agedmedicine.diseasePrognosisKidney NeoplasmsSurvival RatePleomorphism (cytology)Lymphatic MetastasisCohortFemaleNeoplasm GradingbusinessHuman pathology
researchProduct

Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2…

2012

Abstract Background: Previously, small studies have found that BRCA1 and BRCA2 breast tumors differ in their pathology. Analysis of larger datasets of mutation carriers should allow further tumor characterization. Methods: We used data from 4,325 BRCA1 and 2,568 BRCA2 mutation carriers to analyze the pathology of invasive breast, ovarian, and contralateral breast cancers. Results: There was strong evidence that the proportion of estrogen receptor (ER)-negative breast tumors decreased with age at diagnosis among BRCA1 (P-trend = 1.2 × 10−5), but increased with age at diagnosis among BRCA2, carriers (P-trend = 6.8 × 10−6). The proportion of triple-negative tumors decreased with age at diagnos…

OncologyPathologyendocrine system diseasesEpidemiologyGenes BRCA2Genes BRCA1Estrogen receptorGene mutation0302 clinical medicineCancer screeningMedicineskin and connective tissue diseasesEstrogen Receptor StatusOvarian Neoplasms0303 health sciencesMiddle Agedfemale genital diseases and pregnancy complications3. Good healthSerous fluidtriple-negative tumorsOncology030220 oncology & carcinogenesisFemaleestrogen receptorAdultmedicine.medical_specialtyBRCA1; BRCA2; breast cancer; estrogen receptor; triple-negative tumorsHereditary cancer and cancer-related syndromes Genetics and epigenetic pathways of disease [ONCOL 1]Breast NeoplasmsArticle03 medical and health sciencesbreast cancerBreast cancerSDG 3 - Good Health and Well-beingTranslational research [ONCOL 3]Internal medicineHumansGenetic Predisposition to DiseaseGenetics and epigenetic pathways of disease Translational research [NCMLS 6]Germ-Line MutationAged030304 developmental biologyHereditary cancer and cancer-related syndromes [ONCOL 1]business.industryCancerBRCA1medicine.diseaseBRCA2Neoplasm GradingbusinessOvarian cancer
researchProduct